{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-26-000264","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2026-09-01T20:25:14+00:00","discovered_at":"2026-09-01T20:26:00.327779+00:00","generated_at":"2026-09-01T20:26:16.161565+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vertex names Jonathan Poole CFO effective Jan 1, 2027; Wagner stays COO","bullets":["Jonathan Poole, 51, appointed EVP & CFO effective Jan 1, 2027; was SVP Finance since March 2020.","Charles Wagner ceases as CFO on that date but remains EVP & COO.","Poole receives $750,000 base salary and 90% target bonus; severance equals 100% of base plus target bonus.","Change-of-control agreement provides 100% base/target bonus, pro-rated bonus, and full equity vesting on qualifying termination.","Poole previously CFO at Evelo Biosciences (2018-2020) and Genocea Biosciences (2014-2018)."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-26-000264","json":"https://secwatch.observer/filing/0000875320-26-000264.json","markdown":"https://secwatch.observer/filing/0000875320-26-000264.md","text":"https://secwatch.observer/filing/0000875320-26-000264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/0000875320-26-000264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/vrtx-20260827.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T20:26:16.161565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}